Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
US Department of Justice
McKinsey
Fuji
Merck
US Army

Generated: May 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,807,689

« Back to Dashboard

Summary for Patent: 7,807,689
Title:Dipeptidyl peptidase inhibitors
Abstract: The present invention provides a compound of the formula: ##STR00001## or stereoisomers or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, articles of manufacture comprising the same, and methods of using the same.
Inventor(s): Zhang; Zhiyuan (San Diego, CA), Elder; Bruce J. (Wynantskill, NY), Isbester; Paul K. (Castleton, NY), Palmer; Grant J. (Clifton Park, NY), Ulysse; Luckner G. (Albany, NY)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:11/080,992
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,807,689
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,807,689
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation; Dosage form; Delivery; Use;

Drugs Protected by US Patent 7,807,689

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa KAZANO alogliptin benzoate; metformin hydrochloride TABLET;ORAL 203414-002 Jan 25, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN ➤ Try a Free Trial
Takeda Pharms Usa KAZANO alogliptin benzoate; metformin hydrochloride TABLET;ORAL 203414-001 Jan 25, 2013 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN ➤ Try a Free Trial
Takeda Pharms Usa NESINA alogliptin benzoate TABLET;ORAL 022271-001 Jan 25, 2013 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN ➤ Try a Free Trial
Takeda Pharms Usa NESINA alogliptin benzoate TABLET;ORAL 022271-002 Jan 25, 2013 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN ➤ Try a Free Trial
Takeda Pharms Usa NESINA alogliptin benzoate TABLET;ORAL 022271-003 Jan 25, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN ➤ Try a Free Trial
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-004 Jan 25, 2013 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN ➤ Try a Free Trial
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-005 Jan 25, 2013 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 7,807,689

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 048055 ➤ Try a Free Trial
Argentina 103423 ➤ Try a Free Trial
Austria 401320 ➤ Try a Free Trial
Australia 2004318013 ➤ Try a Free Trial
Brazil PI0418639 ➤ Try a Free Trial
Canada 2559302 ➤ Try a Free Trial
China 102079743 ➤ Try a Free Trial
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Covington
McKesson
Deloitte
Federal Trade Commission
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.